# B-51: regional radiation after node-positive breast cancer becomes ypN0

Source: https://onco.cc/key-papers/paper-nsabp-b51-nejm-2025/  
OnCo record `paper-nsabp-b51-nejm-2025` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

B-51 did not show a statistically significant recurrence benefit from regional irradiation in its selected post-chemotherapy ypN0 population. The confidence interval and surgery-specific comparison remain important.

## Summary

Randomised comparison in biopsy-proven cT1 to T3 N1 M0 breast cancer that became pathologically node-negative after neoadjuvant chemotherapy. The 2025 report enrolled 1,641 patients; 1,556 entered the primary-event analysis, 772 with irradiation and 784 without. The primary endpoint counted invasive breast cancer recurrence or death from breast cancer.

The radiation contrast depended on surgery: after lumpectomy, both groups received whole-breast radiation with or without nodal fields; after mastectomy, chest-wall plus nodal irradiation was compared with none. A study-level statement about omission must retain these different strategies.

## Fields

- Kind: Key paper
- Last checked: 2026-11-09
- Tags: education-audit; local-treatment
- Journal: The New England journal of medicine
- Year: 2025
- DOI: 10.1056/nejmoa2414859
- Authors: Mamounas EP, Bandos H, White JR, Julian TB, Khan AJ, Shaitelman SF, Torres MA, Vicini FA, Ganz PA, McCloskey SA, Lucas PC, Gupta N, Li XA, McCormick B, Smith B, Tendulkar RD, Kavadi VS, Matsumoto K, Seaward SA, Irvin WJ, Lin JY, Mutter RW, Muanza TM, Stromberg J, Jagsi R, Weiss AC, Curran WJ, Wolmark N.
- Findings: At median follow-up 59.5 months, 109 primary events occurred: 50 with irradiation and 59 without.; Primary hazard ratio 0.88, 95 percent confidence interval 0.60 to 1.28, p=0.51; reported event-free estimates were 92.7 and 91.8 percent.; Grade 4 adverse events: 0.5 versus 0.1 percent. No deaths related to the protocol therapy were reported.
- What it means: Informs the specified response-adapted radiation question with uncertainty. Residual-node-positive trials and personal treatment decisions require their own population and protocol context.
- Caveats: Nonsignificance does not establish an exactly absent effect or prove safe omission in every population.; The study did not directly test pretreatment N2/N3 disease or residual ypN-positive disease.; ypN0 concerns the nodes examined; it is not by itself a complete breast-and-node response or a whole-body finding.; The registry’s estimated 1,636 and the publication’s enrolled/analysed counts are different source figures and should retain their versions.; The full report permitted ypN0i+ isolated tumour cells but did not collect their frequency or specific outcomes. The analysis used 109 primary events rather than the planned 172 in a protocol-specified time-driven report.

## Sources

- Primary publication identity and abstract: https://pubmed.ncbi.nlm.nih.gov/40466065/
- Full report and methods: https://pmc.ncbi.nlm.nih.gov/articles/PMC12269788/
- Registry: surgery-specific arms and endpoint: https://clinicaltrials.gov/study/NCT01872975

## Connected records

- terms: [Systemic versus local therapy](https://onco.cc/terms/systemic-vs-local-therapy/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- trials: [NSABP B-51 / RTOG 1304](https://onco.cc/trials/nsabp-b51/)

---
JSON: https://onco.cc/api/v1/entities/paper-nsabp-b51-nejm-2025.json